Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols

Silvestrini, Matthew T.; Ingham, Elizabeth S.; Mahakian, Lisa M.; Kheirolomoom, Azadeh; Liu, Yu; Fite, Brett Z.; Tam, Sarah; Tucci, Samantha; Watson, Katherine D.; Wong, Andrew; Monjazeb, Arta M.; Hubbard, Neil E.; Murphy, William J.; Borowsky, Alexander D.; Ferrara, Katherine W.

doi:10.1172/jci.insight.90521

Cited by 88 publications

(123 citation statements)

References 40 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…However, with the improved antigen presentation that can be accomplished with ablative or catheter-directed therapies (Fig. 2), these newer systemic therapies may be further improved [31][32][33][34][35]. As such, there are several ongoing treatment trials that combine immunotherapy with IO.…”

Section: Imaging Guides Intratumoral Deliverymentioning

confidence: 99%

Developing a Roadmap for Interventional Oncology

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Imaging Guides Intratumoral Deliverymentioning

confidence: 99%

Developing a Roadmap for Interventional Oncology

et al. 2018

View full text Add to dashboard Cite

show abstract

“…These strategies rapidly shrink tumors by causing physical stresses or ROS‐mediated damage. Meanwhile, they also trigger the release of tumor‐specific antigens and antigen cross‐presentation by DCs, stimulate the secretion of immunostimulatory factors, potentiate antigen‐specific T‐cell priming, and increase the density of intratumoral lymphoid and myeloid cells . However, local ablative therapies are usually insufficient to fully activate immune responses when applied alone, requiring combination with other interventions for optimal responses …”

Section: Immune‐modulatory Properties Of Cancer Therapiesmentioning

confidence: 99%

“…Expression of CCL2 and CCL7 is also upregulated by certain chemotherapies; these chemokines also crucial for recruiting this immune cell population to tumors by engaging CCR2 . In the presence of local ATP concentrations, CD11b + CD11c + Ly6C hi cells can differentiate into bona fide mature DC capable of cross‐presenting tumor antigens and triggering CTL responses . Moreover, ATP can engage another purinergic receptor, P2RX7, which activates the NLRP3 inflammasome to produce IL‐1 β .…”

Section: Communication Between Dying Cells and Anti‐tumor Immunitymentioning

confidence: 99%

“…Meanwhile, they also trigger the release of tumor-specific antigens and antigen cross-presentation by DCs, stimulate the secretion of immunostimulatory factors, potentiate antigen-specific T-cell priming, and increase the density of intratumoral lymphoid and myeloid cells. 12,15,72,73 However, local ablative therapies are usually insufficient to fully activate immune responses when applied alone, requiring combination with other interventions for optimal responses. 74 Oncolytic viral therapies exert immune-promoting effects through at least two mechanisms: (i) viral replication-induced cancer cell death, which facilitates tumor antigen exposure and cross-presentation;…”

Section: Immune-dependent Tumor Eradicationmentioning

confidence: 99%

“…54 In the presence of local ATP concentrations, CD11b + CD11c + Ly6C hi cells can differentiate into bona fide mature DC capable of cross-presenting tumor antigens and triggering CTL responses. 72 Moreover, ATP can engage another purinergic receptor, P2RX7, which activates the NLRP3 inflammasome to produce IL-1 β. 50 During chemotherapy, IL-1 β is required to activate γδT17 cells, which subsequently drive CTL responses.…”

Section: Communication Between Dying Cells and Anti-tumor Immunitymentioning

confidence: 99%

See 2 more Smart Citations

The renaissance of anti‐neoplastic immunity from tumor cell demise

Pitt²,

et al. 2017

Immunological Reviews

View full text Add to dashboard Cite

Cancer therapies can temporarily reduce tumor burdens by inducing malignant cell death. However, cancer cure is still far from realization because tumors often gain resistance to current treatment and eventually relapse. Accumulating evidence suggests that successful cancer interventions require anti-tumor immunity. Therapy-induced cell stress responses ultimately result in one or more cell death modalities, including apoptosis, autophagy, necroptosis, and pyroptosis. These irreversible dying processes are accompanied by active or passive release of cell death-associated molecular patterns (CDAMPs), which can be sensed by corresponding pattern recognition receptors (PRR) on tumor-infiltrating immune cells. This crosstalk with the immune system can reawaken immune surveillance in the tumor microenvironment (TME). This review focuses on immune-modulatory properties of anti-cancer regimens and CDAMP-mediated communications between cell stress responses and the immune contexture of TME. In addition, we describe how immunogenic cell death can elicit strong and durable anti-tumor immune responses.

show abstract

Monitoring Melanoma Responses to STING Agonism and Focused Ultrasound Thermal Ablation Using Microneedles and Ultrasensitive Single Molecule Arrays

Dahis,

Dion,

Cryer

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Real‐time monitoring of immune state and response to therapy can provide a means to stratify patients and increase the number of responders who will benefit from approved and emerging immunotherapies. The accessibility of immune cells in the skin provides an opportunity for local immune modulation as well as for noninvasive sampling of disease biomarkers in the skin interstitial fluid (ISF). Here, a monitoring strategy for melanoma immunotherapy is investigated by longitudinal sampling of biomarkers in the skin ISF using Hyaluronic acid (HA)‐based microneedles (MNs). Focused ultrasound ablation and delivery of nanoparticulate stimulator of interferon genes agonist are used as model immunotherapies. It is shown that this combination therapy induces potent inflammatory responses in a melanoma mouse model, promoting tumor elimination and immune memory formation. Indeed, quantifying soluble, protein‐based biomarkers following therapy using conventional immunoassay reveals a pronounced proinflammatory program in the tumor. However, conventional assays fail to detect the low concentration of biomarkers in plasma and in MN‐sampled ISF. It is shown that ultrasensitive single molecule arrays (Simoa) effectively detected proinflammatory biomarkers that are upregulated in response to the therapy in MN‐sampled ISF, in plasma, and in tumors, supporting the feasibility of monitoring melanoma immunotherapy using MNs.

show abstract

Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols

Cited by 88 publications

References 40 publications

Developing a Roadmap for Interventional Oncology

Developing a Roadmap for Interventional Oncology

The renaissance of anti‐neoplastic immunity from tumor cell demise

Monitoring Melanoma Responses to STING Agonism and Focused Ultrasound Thermal Ablation Using Microneedles and Ultrasensitive Single Molecule Arrays

Contact Info

Product

Resources

About